GLP-1 agonists are generally safe in mild to moderate kidney impairment and don't require dose adjustment. However, the GI side effects (nausea, vomiting, diarrhea) can cause dehydration, which can worsen kidney function—stay well hydrated. In severe kidney disease, data is limited and caution is warranted. For liver disease, GLP-1 agonists are actually being studied as a treatment for non-alcoholic fatty liver disease (NAFLD/NASH) with promising results. However, severe liver impairment requires medical guidance. In either case, don't self-prescribe—work with a doctor.